Jazz Pharmaceuticals (JAZZ) Current Assets (2010 - 2026)

Jazz Pharmaceuticals' Current Assets history runs 17 years deep, the most recent figure standing at $4.6 billion for Q1 2026.

• On a quarterly basis, Current Assets rose 11.03% year-over-year to $4.6 billion in Q1 2026; TTM through Mar 2026 was $4.6 billion, a 11.03% increase from a year earlier, with the FY2025 full-year figure at $4.2 billion, down 10.0% from the prior year.
• Current Assets climbed to $4.6 billion in Q1 2026 per JAZZ's latest filing, from $4.2 billion in the prior quarter.
• Across five years, Current Assets topped out at $4.6 billion in Q4 2024 and bottomed at $2.5 billion in Q1 2022.
• The 5-year median for Current Assets is $3.4 billion (2023), against an average of $3.5 billion.
• Across the five-year window, Current Assets decreased 21.03% in 2022 and jumped 35.27% in 2024, its largest moves.
• Year by year, Current Assets stood at $2.6 billion in 2022, then soared by 31.82% to $3.4 billion in 2023, then soared by 34.74% to $4.6 billion in 2024, then slipped by 10.0% to $4.2 billion in 2025, then increased by 10.01% to $4.6 billion in 2026.
• Per Business Quant, the three latest JAZZ Current Assets figures stand at $4.6 billion (Q1 2026), $4.2 billion (Q4 2025), and $3.8 billion (Q3 2025).